Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Mineralys Therapeutics (Nasdaq: MLYS) announced on November 26, 2025 that its Compensation Committee granted an inducement stock option covering 146,000 shares to one new non-executive employee on November 24, 2025.
Mineralys Therapeutics (Nasdaq: MLYS) announced on November 26, 2025 that its Compensation Committee granted an inducement stock option covering 146,000 shares to one new non-executive employee on November 24, 2025.
The award was made under the company’s 2025 Employment Inducement Incentive Award Plan and was granted as an inducement material to the employee entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The option vests over four years: 25% on the first anniversary of the vesting commencement date (November 24, 2026) and 1/48th monthly thereafter, subject to continued service.
In the Nov 28 session, MLYS declined 0.55%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement details a routine inducement stock option covering 146,000 shares granted to a new...
Analysis
This announcement details a routine inducement stock option covering 146,000 shares granted to a new non‑executive employee under Nasdaq Listing Rule 5635(c)(4), with vesting over four years. In context, more material drivers have recently included pivotal lorundrostat data and Q3 2025 results highlighting $593.6M in cash and progress toward an NDA. Investors may focus on upcoming regulatory milestones and any further equity or insider activity disclosed in future filings.
Key Figures
Inducement option size:146,000 sharesVesting schedule:4 yearsInitial vesting:25%+5 more
Inducement option size
146,000 shares
Granted to one new non-executive employee on Nov 24, 2025
Vesting schedule
4 years
Inducement stock option vests over four-year period
Initial vesting
25%
Vests on first anniversary of vesting commencement date
Ongoing vesting rate
1/48th monthly
Monthly vesting after first anniversary, subject to continued service
Vesting start date
November 24, 2025
Vesting commencement date for the inducement option
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease (CKD) is a long-term decline in the kidneys’ ability to filter waste and balance fluids and chemicals in the body, often progressing slowly over months or years; think of it as a filter that gradually becomes clogged and less effective. It matters to investors because CKD drives demand for drugs, dialysis, transplants, diagnostics and related medical devices, influences healthcare costs and reimbursement decisions, and is a common target for clinical trials and regulatory review.
obstructive sleep apnea (OSA)medical
"chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases"
A sleep disorder where a person repeatedly stops breathing or breathes very shallowly during sleep because the airway partly or fully closes, causing snoring, daytime tiredness, and other health risks. Investors care because it drives demand for medical devices, diagnostics, treatments, and ongoing healthcare costs—similar to a chronic equipment failure in a factory that reduces output and increases maintenance and regulatory oversight, affecting revenue, reimbursement and long‑term market growth.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, announced today that on"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
inducement stock optionfinancial
"granted an inducement stock option award covering 146,000 shares of"
An inducement stock option is a grant of the right to buy company shares given to a new or existing employee as a special hiring or retention incentive, similar to offering a signing bonus but paid in future stock. Investors care because these options can motivate managers to grow the business and align their interests with shareholders, while also increasing the total number of shares over time and potentially diluting existing ownership and earnings per share.
equity awardsfinancial
"Plan, which provides for the granting of equity awards to new employees"
Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.
Nasdaq Listing Rule 5635(c)(4)regulatory
"the employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
common stockfinancial
"stock option award covering 146,000 shares of Mineralys common stock to"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
RADNOR, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on November 24, 2025, the Compensation Committee of Mineralys’ Board of Directors granted an inducement stock option award covering 146,000 shares of Mineralys common stock to one new non-executive employee.
The award was granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option will vest over a four-year period, with 25% of the total shares underlying the option vesting on the first anniversary of the award’s vesting commencement date, November 24, 2025, and 1/48th of the total shares underlying the option vesting following each one-month period thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Mineralys
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Mineralys Therapeutics (MLYS) announce on November 26, 2025 about a stock option grant?
Mineralys announced a grant of an inducement stock option covering 146,000 shares to one new non-executive employee, dated November 24, 2025.
Under which plan was the Mineralys (MLYS) inducement award granted?
The award was granted under the company’s 2025 Employment Inducement Incentive Award Plan.
What is the vesting schedule for the Mineralys (MLYS) 146,000-share option awarded November 24, 2025?
The option vests over four years: 25% on the first anniversary of November 24, 2025, then 1/48th of the total shares vest each month thereafter, subject to continued service.
Why did Mineralys (MLYS) use Nasdaq Listing Rule 5635(c)(4) for this award?
The company said the award was an inducement material to the new employee entering employment and was granted in accordance with Nasdaq Listing Rule 5635(c)(4).
How many employees received the inducement award from Mineralys (MLYS) on November 24, 2025?
One new non-executive employee received the inducement stock option covering 146,000 shares.
Does the Mineralys (MLYS) announcement state any immediate dilution or financial impact from the 146,000-share option?
The announcement describes the grant and vesting schedule only and does not provide figures or commentary on dilution or immediate financial impact.
